European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS

Spermidine in hypertension: therapeutic potential and novel mechanisms

Descripción del proyecto

¿Es la espermidina un nuevo medicamento contra la hipertensión?

La hipertensión es la principal causa de enfermedad cardiovascular y tan solo un tercio de los pacientes consigue un control eficaz de la tensión arterial con los medicamentos actuales. La evidencia acumulada indica que la espermidina, un activador endógeno de la autofagia y suplemento dietético, está correlacionada con la tensión arterial baja en humanos. El proyecto SPeR-ToNE, financiado con fondos europeos, aprovechará esta observación para aportar información sobre el mecanismo por el cual la espermidina contrarresta la hipertensión. Los investigadores aplicarán un gran número de técnicas de vanguardia, modelos animales y muestras humanas para estudiar la diafonía entre el control de la tensión arterial y la autofagia. Los resultados allanarán el camino para el desarrollo de nuevas intervenciones contra la hipertensión.

Objetivo

Hypertension pharmacotherapy, albeit fairly effective, is far from ideal and adequate blood pressure control is only achieved in one third of patients. As such, hypertension is still the global leading cause of cardiovascular disease and mortality. In this regard, we have recently discovered that higher intake of the caloric restriction mimetic spermidine – a potent inducer of the cellular quality control mechanism, autophagy – correlates with lower blood pressure in humans. Administering spermidine to animals also delays the development of hypertension and vascular aging, suggesting it might be useful for disease prevention. However, whether spermidine can be used for therapy, as urgently needed in patients, is still unknown. Thus, the main objective of this proposal is to elucidate the therapeutic benefit of spermidine in established experimental hypertension. Applying a multitude of cutting-edge techniques, including knockout of autophagy genes and metabolic flux, we will provide key mechanistic insights on whether spermidine counteracts hypertension via activating autophagy, upregulating the arginine-nitric oxide axis, or both. With the ultimate goal of translating our findings from animals to humans, we will validate the clinical relevance of these mechanisms in patients' samples. Hence, this proposal will not only reveal a potential novel treatment for patients with hypertension, but will also study a previously understudied cross-talk between blood pressure control and autophagy. If true, we anticipate the project results to pave the way for a novel concept for hypertension therapy. Considering that the work will be done at a leading multi-disciplinary research group, where the researcher will bring expertise in cardiology and receive advanced training in cell biology and molecular metabolism, the fellowship will substantially advance his academic career to eventually reach his goal of leading his own research team.

Coordinador

INSTITUT GUSTAVE ROUSSY
Aportación neta de la UEn
€ 196 707,84
Dirección
Rue Camille Desmoulins 39
94805 Villejuif
Francia

Ver en el mapa

Región
Ile-de-France Ile-de-France Val-de-Marne
Tipo de actividad
Research Organisations
Enlaces
Coste total
€ 196 707,84